292 related articles for article (PubMed ID: 20509933)
1. Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer.
Montgomery B; Nelson PS; Vessella R; Kalhorn T; Hess D; Corey E
BMC Cancer; 2010 May; 10():244. PubMed ID: 20509933
[TBL] [Abstract][Full Text] [Related]
2. Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA; Marck BT; Plymate SR; Vessella RL; Balk S; Matsumoto AM; Nelson PS; Montgomery RB
Clin Cancer Res; 2011 Sep; 17(18):5913-25. PubMed ID: 21807635
[TBL] [Abstract][Full Text] [Related]
3. Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R; Evaul K; Sharma KK; Chang KH; Yoshimoto J; Liu J; Auchus RJ; Sharifi N
Clin Cancer Res; 2012 Jul; 18(13):3571-9. PubMed ID: 22753664
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.
Corey E; Quinn JE; Emond MJ; Buhler KR; Brown LG; Vessella RL
Clin Cancer Res; 2002 Apr; 8(4):1003-7. PubMed ID: 11948106
[TBL] [Abstract][Full Text] [Related]
5. Receptor isoform and ligand-specific modulation of dihydrotestosterone-induced prostate specific antigen gene expression and prostate tumor cell growth by estrogens.
Zhu YS; Cai LQ; Huang Y; Fish J; Wang L; Zhang ZK; Imperato-McGinley JL
J Androl; 2005; 26(4):500-8; discussion 509-10. PubMed ID: 15955889
[TBL] [Abstract][Full Text] [Related]
6. Suppression of DHT-induced paracrine stimulation of endothelial cell growth by estrogens via prostate cancer cells.
Wen J; Zhao Y; Li J; Weng C; Cai J; Yang K; Yuan H; Imperato-McGinley J; Zhu YS
Prostate; 2013 Jul; 73(10):1069-81. PubMed ID: 23423946
[TBL] [Abstract][Full Text] [Related]
7. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
Wu JD; Odman A; Higgins LM; Haugk K; Vessella R; Ludwig DL; Plymate SR
Clin Cancer Res; 2005 Apr; 11(8):3065-74. PubMed ID: 15837762
[TBL] [Abstract][Full Text] [Related]
8. Adrenal androgens rescue prostatic dihydrotestosterone production and growth of prostate cancer cells after castration.
Wu Y; Tang L; Azabdaftari G; Pop E; Smith GJ
Mol Cell Endocrinol; 2019 Apr; 486():79-88. PubMed ID: 30807787
[TBL] [Abstract][Full Text] [Related]
9. Contribution of Adrenal Glands to Intratumor Androgens and Growth of Castration-Resistant Prostate Cancer.
Mostaghel EA; Zhang A; Hernandez S; Marck BT; Zhang X; Tamae D; Biehl HE; Tretiakova M; Bartlett J; Burns J; Dumpit R; Ang L; Matsumoto AM; Penning TM; Balk SP; Morrissey C; Corey E; True LD; Nelson PS
Clin Cancer Res; 2019 Jan; 25(1):426-439. PubMed ID: 30181386
[TBL] [Abstract][Full Text] [Related]
10. Intracrine androgen biosynthesis in renal cell carcinoma.
Lee GT; Han CS; Kwon YS; Patel R; Modi PK; Kwon SJ; Faiena I; Patel N; Singer EA; Ahn HJ; Kim WJ; Kim IY
Br J Cancer; 2017 Mar; 116(7):937-943. PubMed ID: 28253524
[TBL] [Abstract][Full Text] [Related]
11. Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
Titus MA; Zeithaml B; Kantor B; Li X; Haack K; Moore DT; Wilson EM; Mohler JL; Kafri T
PLoS One; 2012; 7(1):e30192. PubMed ID: 22272301
[TBL] [Abstract][Full Text] [Related]
12. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
Arnold JT; Le H; McFann KK; Blackman MR
Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
[TBL] [Abstract][Full Text] [Related]
13. 17alpha-estradiol inhibits LAPC-4 prostatic tumor cell proliferation in cell cultures and tumor growth in xenograft animals.
Qiao Y; Zhang ZK; Cai LQ; Tan C; Imperato-McGinley JL; Zhu YS
Prostate; 2007 Dec; 67(16):1719-28. PubMed ID: 17879940
[TBL] [Abstract][Full Text] [Related]
14. HE3235 inhibits growth of castration-resistant prostate cancer.
Koreckij TD; Trauger RJ; Montgomery RB; Pitts TE; Coleman I; Nguyen H; Reading CL; Nelson PS; Vessella RL; Corey E
Neoplasia; 2009 Nov; 11(11):1216-25. PubMed ID: 19881957
[TBL] [Abstract][Full Text] [Related]
15. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
16. Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
Mostaghel EA; Morgan A; Zhang X; Marck BT; Xia J; Hunter-Merrill R; Gulati R; Plymate S; Vessella RL; Corey E; Higano CS; Matsumoto AM; Montgomery RB; Nelson PS
PLoS One; 2014; 9(10):e111545. PubMed ID: 25356728
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.
Montgomery RB; Mostaghel EA; Vessella R; Hess DL; Kalhorn TF; Higano CS; True LD; Nelson PS
Cancer Res; 2008 Jun; 68(11):4447-54. PubMed ID: 18519708
[TBL] [Abstract][Full Text] [Related]
18. New agents and strategies for the hormonal treatment of castration-resistant prostate cancer.
Sharifi N
Expert Opin Investig Drugs; 2010 Jul; 19(7):837-46. PubMed ID: 20524793
[TBL] [Abstract][Full Text] [Related]
19. The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer.
Sharifi N
J Investig Med; 2012 Feb; 60(2):504-7. PubMed ID: 22064602
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer.
Hamid AR; Pfeiffer MJ; Verhaegh GW; Schaafsma E; Brandt A; Sweep FC; Sedelaar JP; Schalken JA
Mol Med; 2013 Jan; 18(1):1449-55. PubMed ID: 23196782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
